Key result
The WiSE-CRT system successfully achieved biventricular pacing in 97.1% of patients at 1 month, demonstrating feasibility for patients ineligible for conventional cardiac resynchronization therapy.
This editorial discusses the clinical implications and future direction of wireless endocardial left ventricular pacing (WiSE-CRT) for cardiac resynchronization therapy.
Cardiac resynchronization therapy (CRT) nowadays is an important part of invasive heart failure therapy (1). Furthermore, it gains increasing recognition for anti-bradycardia pacemaker indications with an expected high burden of ventricular pacing by reducing cardiac remodeling (2). With a considerable number of CRT implantations worldwide, the impact of the recent clinical evaluation of wireless endocardial left ventricular (LV) pacing with a novel wireless cardiac resynchronization system (WiSE-CRT, EBR Systems, Sunnyvale, California, USA) by Reddy et al . 2017 should be further debated (3).
No takes yet. Share an insight, caveat, or question.
Holubec et al. (2018) conducted an editorial in Heart failure (n=35). WiSE-CRT system (wireless endocardial left ventricular pacing) was evaluated on 12-lead ECG showing biventricular pacing at 1 month. The WiSE-CRT system successfully achieved biventricular pacing in 97.1% of patients at 1 month, demonstrating feasibility for patients ineligible for conventional cardiac resynchronization therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: